Biotech Values

[DewDiligence]

MRK—so the key now becomes rather it has to have rems program or not. That’s what will determine if its 500 million dollar drug verses 2-3 billion???

The REMS, if there is one, will not make a 6x difference or have anywhere near that kind of effect in the sales potential of suvorexant. Rather, what will determine whether this is a medium-selling drug or a huge-selling drug is how well it actually works in the real world.